title: [Use of moxifloxacin in tuberculosis regimen in a French teaching hospital].
abstract: OBJECTIVE
  To evaluate retrospectively indications of moxifloxacin prescriptions in inpatients with tuberculosis in a referent teaching hospital.
  
  
  METHODS
  All patients hospitalized at Bichat-Claude Bernard hospital and who had an active tuberculosis disease with a tuberculosis regimen including moxifloxacin were included. Medical charts were retrospectively reviewed for all these patients over 21 months. Data collected were reasons for introduction of moxifloxacin in regimen.
  
  
  RESULTS
  Out of the 23 patients included in the study, 13 of them had a recurrence of tuberculosis. Several reasons for introduction of moxifloxacin were recorded and one prescription can be associated with one or more reasons: an extra pulmonary tuberculosis or disseminated tuberculosis (16 cases), an intolerance to other anti-tuberculosis drugs (13 cases), a medical history of therapeutic failure or a proved or suspected drug-resistant Mycobacterium tuberculosis (12 cases) or to avoid drug interactions (two cases).
  
  
  CONCLUSIONS
  This retrospective study in our hospital highlights that drug-resistance was not the first reason for introduction of moxifloxacin in anti-tuberculosis regimen. One major indication was bad tolerance to other first-line regimen drugs. A better supervision of the moxifloxacin prescription in tuberculosis regimen is needed in order to limit its ecological impact.
authors.affiliation: Service de pharmacie, hôpital Bichat-Claude-Bernard, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Berdot
authors.forename: E
authors.initials: E
authors.lastname: Papy
authors.forename: C
authors.initials: C
authors.lastname: Rioux
authors.forename: S
authors.initials: S
authors.lastname: Diamantis
authors.forename: R
authors.initials: R
authors.lastname: Ruimy
authors.forename: M-C
authors.initials: MC
authors.lastname: Dombret
authors.forename: P
authors.initials: P
authors.lastname: Arnaud
authors.forename: E
authors.initials: E
authors.lastname: Bouvet
mesh_terms: D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D015897:Comorbidity; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D004363:Drug Utilization; D005260:Female; D024841:Fluoroquinolones; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000453:epidemiology; D006785:Hospitals, University / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin